A
Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
NASDAQ:AQST
Price:
4.07 USD
3.56%
Market Closed
Updated:
Apr 28, 2024
Aquestive Therapeutics Inc
Revenue
|
Aquestive Therapeutics Inc
Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Revenue
$50.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45B
|
CAGR 3-Years
2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$60.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Aquestive Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Aquestive Therapeutics Inc
Aquestive Therapeutics Inc
|
Total Revenue:
50.6m
USD
|
|
United States:
37.1m
USD
|
|
Ex-United States:
13.5m
USD
|
Breakdown by Segments
Aquestive Therapeutics Inc
Aquestive Therapeutics Inc
|
Total Revenue:
50.6m
USD
|
|
Manufacture And Supply Revenue:
43.8m
USD
|
|
License And Royalty Revenue:
5.4m
USD
|
|
Co-Development And Research Fees:
1.4m
USD
|
See Also
What is Aquestive Therapeutics Inc's Revenue?
Revenue
50.6m
USD
50.6m
USD
Based on the financial report for Dec 31, 2023, Aquestive Therapeutics Inc's Revenue amounts to 50.6m USD.
What is Aquestive Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
-6%
-6%
Over the last year, the Revenue growth was 6%. The average annual Revenue growth rates for Aquestive Therapeutics Inc have been 3% over the past three years , -6% over the past five years .
You don't have any saved screeners yet
